Verona Cash And Short Term Investments vs Common Stock Shares Outstanding Analysis

VRNA Stock  USD 41.42  2.16  5.50%   
Verona Pharma financial indicator trend analysis is much more than just breaking down Verona Pharma PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verona Pharma PLC is a good investment. Please check the relationship between Verona Pharma Cash And Short Term Investments and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cash And Short Term Investments vs Common Stock Shares Outstanding

Cash And Short Term Investments vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verona Pharma PLC Cash And Short Term Investments account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Verona Pharma's Cash And Short Term Investments and Common Stock Shares Outstanding is -0.42. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Verona Pharma PLC, assuming nothing else is changed. The correlation between historical values of Verona Pharma's Cash And Short Term Investments and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Verona Pharma PLC are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Cash And Short Term Investments i.e., Verona Pharma's Cash And Short Term Investments and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.42
Relationship DirectionNegative 
Relationship StrengthVery Weak

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Verona Pharma PLC balance sheet. This account contains Verona Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Verona Pharma PLC fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Verona Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At present, Verona Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 582.8 K, whereas Sales General And Administrative To Revenue is forecasted to decline to 17.17.
 2021 2022 2023 2024 (projected)
Research Development79.4M49.3M17.3M19.8M
Depreciation And Amortization629K636K679.6K713.6K

Verona Pharma fundamental ratios Correlations

0.541.0-0.97-0.970.510.980.860.920.331.00.79-0.420.330.90.990.941.00.980.510.86-0.760.260.90.881.0
0.540.54-0.55-0.550.810.470.510.610.30.510.78-0.210.710.590.540.50.530.550.980.26-0.760.280.230.720.53
1.00.54-0.97-0.960.480.980.830.930.351.00.78-0.430.350.910.990.911.00.980.510.83-0.750.270.870.870.99
-0.97-0.55-0.970.96-0.46-0.99-0.83-0.97-0.36-0.97-0.740.36-0.44-0.87-0.97-0.88-0.97-0.99-0.53-0.820.69-0.07-0.87-0.83-0.98
-0.97-0.55-0.960.96-0.58-0.97-0.92-0.94-0.29-0.96-0.840.45-0.41-0.81-0.99-0.94-0.96-0.98-0.51-0.890.7-0.11-0.89-0.86-0.98
0.510.810.48-0.46-0.580.450.70.570.070.470.81-0.270.40.510.540.620.50.540.690.38-0.520.220.390.560.51
0.980.470.98-0.99-0.970.450.860.950.320.980.73-0.360.340.850.980.920.980.990.450.88-0.660.070.930.820.99
0.860.510.83-0.83-0.920.70.860.820.050.840.77-0.360.220.70.90.910.840.880.440.81-0.550.030.830.710.87
0.920.610.93-0.97-0.940.570.950.820.390.920.8-0.40.550.830.940.850.920.980.580.79-0.630.010.830.790.95
0.330.30.35-0.36-0.290.070.320.050.390.330.330.030.440.390.310.20.340.330.340.21-0.490.090.210.410.33
1.00.511.0-0.97-0.960.470.980.840.920.330.76-0.420.310.910.990.931.00.970.490.85-0.750.270.90.870.99
0.790.780.78-0.74-0.840.810.730.770.80.330.76-0.450.610.730.810.80.780.80.710.71-0.770.290.640.870.79
-0.42-0.21-0.430.360.45-0.27-0.36-0.36-0.40.03-0.42-0.45-0.37-0.29-0.44-0.34-0.42-0.44-0.15-0.410.19-0.36-0.35-0.37-0.43
0.330.710.35-0.44-0.410.40.340.220.550.440.310.61-0.370.310.360.220.340.430.740.24-0.47-0.080.110.530.37
0.90.590.91-0.87-0.810.510.850.70.830.390.910.73-0.290.310.860.810.910.860.560.65-0.740.390.740.790.89
0.990.540.99-0.97-0.990.540.980.90.940.310.990.81-0.440.360.860.950.990.990.50.88-0.720.190.90.871.0
0.940.50.91-0.88-0.940.620.920.910.850.20.930.8-0.340.220.810.950.930.910.450.92-0.720.180.940.850.93
1.00.531.0-0.97-0.960.50.980.840.920.341.00.78-0.420.340.910.990.930.970.510.85-0.760.270.890.880.99
0.980.550.98-0.99-0.980.540.990.880.980.330.970.8-0.440.430.860.990.910.970.520.85-0.670.090.890.830.99
0.510.980.51-0.53-0.510.690.450.440.580.340.490.71-0.150.740.560.50.450.510.520.22-0.780.260.180.720.5
0.860.260.83-0.82-0.890.380.880.810.790.210.850.71-0.410.240.650.880.920.850.850.22-0.560.010.950.770.86
-0.76-0.76-0.750.690.7-0.52-0.66-0.55-0.63-0.49-0.75-0.770.19-0.47-0.74-0.72-0.72-0.76-0.67-0.78-0.56-0.5-0.5-0.95-0.71
0.260.280.27-0.07-0.110.220.070.030.010.090.270.29-0.36-0.080.390.190.180.270.090.260.01-0.50.020.390.19
0.90.230.87-0.87-0.890.390.930.830.830.210.90.64-0.350.110.740.90.940.890.890.180.95-0.50.020.690.9
0.880.720.87-0.83-0.860.560.820.710.790.410.870.87-0.370.530.790.870.850.880.830.720.77-0.950.390.690.86
1.00.530.99-0.98-0.980.510.990.870.950.330.990.79-0.430.370.891.00.930.990.990.50.86-0.710.190.90.86
Click cells to compare fundamentals

Verona Pharma Account Relationship Matchups

Verona Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets59.2M204.2M186.6M259.5M308.1M323.5M
Total Current Liabilities12.6M14.2M33.4M19.0M8.7M7.7M
Total Stockholder Equity44.4M184.9M148.0M230.5M249.3M261.7M
Net Debt(28.8M)(182.0M)(142.6M)(217.2M)(220.4M)(209.4M)
Retained Earnings(131.9M)(207.1M)(263.7M)(333.1M)(388.4M)(369.0M)
Accounts Payable1.9M178K10.0M2.9M3.5M3.7M
Cash30.1M188.0M148.4M227.8M271.8M285.4M
Non Current Assets Total5.5M1.7M16.5M16.5M18.4M19.3M
Cash And Short Term Investments40.3M188.0M148.4M227.8M271.8M285.4M
Net Receivables9.8M8.3M15.6M9.3M11.0M11.5M
Common Stock Shares Outstanding13.2M32.9M59.1M66.1M79.3M75.3M
Liabilities And Stockholders Equity59.2M204.2M186.6M259.5M308.1M323.5M
Inventory3.5M4.5M4.0M2.5M1.00.95
Other Current Assets10.2K6.3M6.1M5.9M7.0M7.3M
Other Stockholder Equity158.0M364.7M384.5M527.6M599.5M629.5M
Total Liab14.8M19.4M38.6M29.0M58.8M61.8M
Total Current Assets53.7M202.5M170.1M243.0M289.7M304.2M
Common Stock6.9M31.8M31.9M40.5M42.8M44.9M
Other Current Liab10.1M12.4M22.6M15.2M4.0M5.9M
Property Plant And Equipment Net1.3M1.2M979K927K2.9M3.0M
Good Will596.0K559.6K578.2K545K490.5K466.0K
Short Term Investments66.0M57.0M10.3M10.3M11.8M20.1M
Property Plant And Equipment Gross43K1.2M979K927K2.9M3.0M
Net Tangible Assets42.2M184.3M167.7M229.9M264.4M277.6M
Property Plant Equipment1.4M1.2M979K927K1.1M1.1M
Short Term Debt603.1K1.6M648K675K1.2M694.2K
Non Current Liabilities Total2.2M5.1M5.2M10.0M50.1M52.7M
Capital Lease Obligations951K1.3M934K880K3.0M3.1M
Short Long Term Debt Total1.2M5.9M5.8M10.6M51.3M53.9M
Current Deferred Revenue0.010.9M22.4M1.01.151.09
Net Invested Capital44.4M189.5M152.9M240.2M297.7M174.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.00)
Revenue Per Share
0.07
Return On Assets
(0.28)
Return On Equity
(0.78)
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.